Sue Ashwell

Susan Ashwell, Ph.D., has worked in R&D in both biotech and pharma for more than 25 years, helping advance clinical candidates across a variety of target classes and therapeutic areas, including oncology, CNS disorders, inflammation, and immunology.

Prior to joining Civetta, Sue was Head of Medicinal Chemistry at UCB, Cambridge (through the acquisition of Ra Pharmaceuticals) where she had multiple roles in group and project leadership and worked to coordinate external collaborations. Before her role at Ra Pharmaceuticals, Sue was a Senior Director in Chemistry at FORMA Therapeutics were led the FT-2102 program, currently in clinical development. Sue joined FORMA from AstraZeneca where she was a member of both local and global cancer chemistry and cancer management teams responsible for setting strategy, portfolio delivery, and governance, including resource and budget allocation. Before her time at AstraZeneca, she was a medicinal chemist, group, and project leader with Wyeth-Ayerst Research.

Sue received her Ph.D. in Organic Chemistry from the University of Newcastle upon Tyne, prior to conducting postdoctoral research at the University of Illinois at Chicago and Imperial College, London.